Semaglutide in the treatment of type 2 diabetes mellitus： rapid health technology assessment

WANG Sihua; WANG Sheng; WANG Yan; LUAN Jiajie

doi:10.6039/j.issn.1001-0408.2023.12.18

您当前的位置：

首页 >

文章列表页 >

Semaglutide in the treatment of type 2 diabetes mellitus： rapid health technology assessment

更新时间：2023-06-26

- Semaglutide in the treatment of type 2 diabetes mellitus： rapid health technology assessment
- ZHONGGUO YAOFANG Vol. 34, Issue 12, Pages: 1503-1508(2023)
- 作者机构：
  
  1.皖南医学院药学院，安徽芜湖　241002
  2.皖南医学院弋矶山医院药学部，安徽芜湖　241001
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.12.18
  CLC： R977.1+5
- Published：30 June 2023，
  
  Received：27 December 2022，
  
  Revised：30 May 2023，
扫描看全文
王思骅,汪盛,王岩等.司美格鲁肽治疗2型糖尿病的快速卫生技术评估 ^Δ[J].中国药房,2023,34(12):1503-1508.

WANG Sihua,WANG Sheng,WANG Yan,et al.Semaglutide in the treatment of type 2 diabetes mellitus： rapid health technology assessment[J].ZHONGGUO YAOFANG,2023,34(12):1503-1508.
王思骅,汪盛,王岩等.司美格鲁肽治疗2型糖尿病的快速卫生技术评估 ^Δ[J].中国药房,2023,34(12):1503-1508. DOI： 10.6039/j.issn.1001-0408.2023.12.18.

WANG Sihua,WANG Sheng,WANG Yan,et al.Semaglutide in the treatment of type 2 diabetes mellitus： rapid health technology assessment[J].ZHONGGUO YAOFANG,2023,34(12):1503-1508. DOI： 10.6039/j.issn.1001-0408.2023.12.18.

摘要

目的

评价司美格鲁肽治疗2型糖尿病（T2DM）的有效性、安全性和经济性，为临床用药提供参考。

方法

采用快速卫生技术评估（HTA）方法。计算机检索PubMed、Embase、Cochrane Library、Web of Science、中国知网、万方数据、中国生物医学文献服务系统及国内外HTA机构官方网站，收集司美格鲁肽治疗T2DM的HTA报告、系统评价/Meta分析和药物经济学研究，检索时限均为建库起至2022年5月1日。资料提取和质量评价后，对纳入研究的结果进行描述性分析。

结果

共纳入22篇文献，包括7篇Meta分析和15篇药物经济学研究。有效性和安全性方面，司美格鲁肽在控制糖化血红蛋白（HbA1c）、空腹血糖、餐后平均血糖、体质量指数、HbA1c水平＜7%达标率方面疗效显著，未增加低血糖和严重不良反应的发生风险，但胃肠道不良反应发生率较高。经济性方面，国外研究结果显示，与其他胰高血糖素样肽1受体激动剂、钠-葡萄糖协同转运蛋白2抑制剂、二肽基肽酶4抑制剂等比较，司美格鲁肽均具有经济学优势；基于中国卫生体系角度下的研究表明，以2020年我国人均国内生产总值（72 477元）作为意愿支付阈值时，司美格鲁肽较度拉糖肽具有经济学优势。

结论

司美格鲁肽治疗T2DM的有效性和安全性均较好，且与其他治疗药物比较具有经济学优势，但需注意胃肠道反应的发生风险。

Abstract

OBJECTIVE

To evaluate the efficacy， safety and cost-effectiveness of semaglutide in the treatment of type 2 diabetes mellitus （T2DM）， and to provide reference for clinical drug use.

METHODS

Rapid health technology assessment was adopted. Retrieved from PubMed， Embase， Cochrane Library， Web of Science， CNKI， Wanfang database， CBM， domestic and foreign HTA official websites， HTA reports， systematic evaluation/meta-analysis and pharmacoeconomic studies about semaglutide in the treatment of T2DM were collected during the inception to May 1st， 2022. After data extraction and quality evaluation， descriptive analysis was performed on the results of included studies.

RESULTS

A total of 22 pieces of literature were included， involving 7 meta-analyses and 15 pharmacoeconomic studies. In terms of efficacy and safety， semaglutide showed significant advantages in controlling glycated hemoglobin （HbA1c）， fasting blood glucose， postprandial mean glucose， body mass index and achieving a target of glycosylated hemoglobin level ＜7%； also， there was no increased risk of hypoglycaemia or the incidence of serious adverse effects， but the risk of gastrointestinal adverse effects was significantly higher than other interventions. In terms of cost-effectiveness， results of foreign studies showed that semaglutide was more cost-effective， compared with other glucagon-like peptide-1 receptor agonists， sodium-glucose transporter protein 2 inhibitors， dipeptidyl peptidase-4 inhibitors. Research based on the perspective of China’s health system showed that semaglutide had a clear cost-effectiveness advantage over dulaglutide when using GDP per capita in 2020 （72 477 yuan） as the payment threshold.

CONCLUSIONS

The semaglutide has excellent efficacy and good safety for the treatment of T2DM， with cost-effectiveness advantages over a number of drugs， but attention should be paid to the occurrence of gastrointestinal adverse effects.

关键词

司美格鲁肽2型糖尿病有效性安全性经济性快速卫生技术评估

Keywords

type 2 diabetes mellitusefficacysafetycost-effectivenessrapid health technology assessment

references

WANG L M，PENG W，ZHAO Z P，et al. Prevalence and treatment of diabetes in China，2013-2018[J]. JAMA，2021，326（24）：2498-2506.

宣建伟，程远远，徐文洁，等. 2型糖尿病全球首创新药卫生技术评估的策略及其启示[J]. 中国药物经济学，2021，16（4）：16-25.

中华医学会糖尿病学分会. 中国2型糖尿病防治指南：2020年版[J]. 国际内分泌代谢杂志，2021，41（5）：482-548.

崔佳乐，杨艳，彭雅茗，等. GLP-1RA在2型糖尿病中的应用进展[J]. 医学综述，2021，27（4）：778-782，787.

纪立农. 胰高血糖素样肽1受体激动剂周制剂中国证据与专家指导建议[J]. 中国糖尿病杂志，2022，30（6）：405-411.

O’ROURKE B，OORTWIJN W，SCHULLER T. Response to redefining health technology assessment：a comment on “the new definition of health technology assessment：a milestone in international collaboration”[J]. Int J Technol Assess Health Care，2022，38（1）：e55.

唐惠林，门鹏，翟所迪. 药物快速卫生技术评估方法及应用[J]. 临床药物治疗杂志，2016，14（2）：1-4.

顾歆纯，门鹏，翟所迪. 艾塞那肽的快速卫生技术评估[J]. 中国医院药学杂志，2017，37（15）：1489-1493.

INAHTA Secretariat. A checklist for health technology assessment reports[EB/OL]. [2022-11-01].https：//www.inahta.org/wp-content/uploads/2014/04/INAHTA_HTA_Chec-klist_English.pdfhttps://www.inahta.org/wp-content/uploads/2014/04/INAHTA_HTA_Chec-klist_English.pdf.

SHEA B J，REEVES B C，WELLS G，et al. AMSTAR 2：a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions，or both[J]. BMJ，2017，358：j4008.

HUSEREAU D，DRUMMOND M，AUGUSTOVSKI F，et al. Consolidated Health Economic Evaluation Repor-ting Standards 2022（CHEERS 2022）statement：updated reporting guidance for health economic evaluations[J]. BMC Health Serv Res，2022，22（1）：114.

ALSUGAIR H A，ALSHUGAIR I F，ALHARBI T J，et al. Weekly semaglutide vs. liraglutide efficacy profile：a network meta-analysis[J]. Healthcare（Basel），2021，9（9）：1125.

TSAPAS A，KARAGIANNIS T，AVGERINOS I，et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes[J]. Ann Intern Med，2021，174（1）：141.

HUSSEIN H，ZACCARDI F，KHUNTI K，et al. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists：a systematic review and network meta-analysis[J]. Diabetes Obes Metab，2020，22（7）：1035-1046.

KANTERS S，WILKINSON L，VRAZIC H，et al. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs：a systematic literature review and network meta-analysis[J]. BMJ Open，2019，9（7）：e023458.

WITKOWSKI M，WILKINSON L，WEBB N，et al. A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously recei-ving basal insulin[J]. Diabetes Ther，2018，9（3）：1233-1251.

SHI F H，LI H，CUI M，et al. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes：a systematic review and meta-analysis of randomized controlled trials[J]. Front Pharmacol，2018，9：576.

KANTERS S，WILKINSON L，LOPES S，et al. Syste-matic literature review and indirect treatment comparison of the efficacy of semaglutide versus empagliflozin as add-on to basal insulin[J]. Value Health，2017，20（9）：A474.

STAFFORD S，BECH P G，FRIDHAMMAR A，et al. Cost-effectiveness of once-weekly semaglutide 1 mg versus canagliflozin 300 mg in patients with type 2 diabetes mellitus in a Canadian setting[J]. Appl Health Econ Health Policy，2022，20（4）：543-555.

RUAN Z，UNG C O L，SHEN Y，et al. Long-term cost-effectiveness analysis of once-weekly semaglutide versus dulaglutide in patients with type 2 diabetes with in-adequate glycemic control in China[J]. Diabetes Ther，2022，13（10）：1737-1753.

ZUPA M F，CODARIO R A，SMITH K J. Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for type 2 diabetes[J]. J Comp Eff Res，2021，10（15）：1133-1141.

RUAN Z，YANG L S，SHI H H，et al. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 diabetes：a syste-matic literature review[J]. Expert Rev Pharmacoecon Outcomes Res，2021，21（2）：221-233.

MARTÍN V，VIDAL J，MALKIN S J P，et al. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide and sitagliptin in the Spanish setting[J]. Adv Ther，2020，37（10）：4427-4445.

JOHANSEN P，CHUBB B，HUNT B，et al. Evaluating the long-term cost-effectiveness of once-weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes in the UK[J]. Adv Ther，2020，37（5）：2427-2441.

HALLÉN N，CARVALHO D，COSTA C，et al. PDB32 A LONG-TERM cost-effectiveness analysis of treatments for type 2 diabetes in Portugal：once-weekly semaglutide 1 mg versus once-daily empagliflozin 25 mg[J]. Value Health，2020，23：S511.

HALLÉN N，DJEKIC D，IOANNIDIS I，et al. PDB36 LONG-TERM cost-effectiveness analyses of once-weekly semaglutide 1 mg versus empagliflozin 25 mg for treatment of type 2 diabetes in three countries：Bosnia and Herzegovina，Greece，and Slovenia[J]. Value Health，2020，23：S512.

GORGOJO-MARTÍNEZ J J，MALKIN S J P，MARTÍN V，et al. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting：once-weekly semaglutide versus empagliflozin[J]. J Med Econ，2020，23（2）：193-203.

VILJOEN A，HOXER C S，JOHANSEN P，et al. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK[J]. Diabetes Obes Metab，2019，21（3）：611-621.

MALKIN S J P，RUSSEL-SZYMCZYK M，PSOTA M，et al. The management of type 2 diabetes with once-weekly semaglutide versus dulaglutide：a long-term cost-effectiveness analysis in Slovakia[J]. Adv Ther，2019，36（8）：2034-2051.

MALKIN S J P，RUSSEL-SZYMCZYK M，LIIDEMANN G，et al. Once-weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes：a long-term cost-effectiveness analysis in Estonia[J]. Diabetes Ther，2019，10（1）：159-176.

HUNT B，MALKIN S J P，MOES R G J，et al. Once-weekly semaglutide for patients with type 2 diabetes：a cost-effectiveness analysis in the Netherlands[J]. BMJ Open Diabetes Res Care，2019，7（1）：e000705.

GÆDE P，JOHANSEN P，TIKKANEN C K，et al. Correction to：management of patients with type 2 diabetes with once-weekly semaglutide versus dulaglutide，exenatide ER，liraglutide and lixisenatide：a cost-effectiveness analysis in the Danish setting[J]. Diabetes Ther，2019，10（4）：1319-1321.

ERICSSON Å，FRIDHAMMAR A. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden[J]. J Med Econ，2019，22（10）：997-1005.

KRISTENSEN S L，RØRTH R，JHUND P S，et al. Cardiovascular，mortality，and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes：a syste-matic review and meta-analysis of cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol，2019，7（10）：776-785.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Rapid health technology assessment of bovine pulmonary surfactant versus porcine ones in the treatment of preterm neonates with respiratory distress syndrome

Efficacy， safety and cost-effectiveness of edaravone dexborneol and compound porcine cerebroside ganglioside in the treatment of acute ischemic stroke

Efficacy and safety comparison of lacosamide and carbamazepine in the treatment of adult patients with newly diagnosed epilepsy

Meta-analysis of efficacy and safety of cabozantinib in the treatment of advanced thyroid cancer

Network meta-analysis of the effectiveness and safety of 3 kinds of snake venom hemocoagulase drugs for hemostasis in abdominal surgery

Related Author

GUO Hua

SHAO Yun

LIU Lanlan

REN Pengfei

FU Qiang

SUN Nan

ZHOU Jianchao

KANG Jian

Related Institution

Dept. of Pharmacy， the First Affiliated Hospital of Zhengzhou University

Dept. of Pharmacy，the Third Affiliated Hospital of Zhengzhou University

Dept. of Pharmacy， the Second Affiliated Hospital of Mudanjiang Medical University， Heilongjiang Mudanjing

College of Pharmacy， Mudanjiang Medical University， Heilongjiang Mudanjing

First Ward， Dept. of Neurology， Huaihe Hospital of Henan University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰